February goes down in the books as an up month that has put the market back to flat for 2010. How should you be positioned for March?
Over the next few weeks, I feel confident that’s how investors will make money, says veteran trader Gary Kaminksy – with contrarian trades.
With Barron’s turning very bullish on generic drugmaker Mylan Labs, should you put money to work in the generic space?
What follows is a roundup of corporate earnings reports for Tuesday, Feb. 15.
On a day when the market seemed confused - moving within relatively a wide range and ending the day to the downside - there were many reasons why this confusion was warranted.
On a day where markets are rattled by sovereign debt issues, yet encouraged that a European bailout of Greece may be imminent, markets have also reacted to domestic developments.
Three out of four prescriptions in the U.S. are filled with generics. But a new, albeit small, survey by a prominent generic drug industry analyst shows even the people filling those pill bottles have issues with generics.
Markets rose on Monday, rebounding off of their worst week since last March. What should investors expect going forward? Dan Genter of RNC Capital Management and David Hefty of Cornerstone Wealth Management shared their outlooks, sector and stock picks.
Here’s our Fast Money Final Trade. Our gang gives you Monday’s best trades, right now.
Corporate donations to the relief effort in Haiti now total more than $106 million according to the U.S. Chamber of Commerce, surpassing the $100 million in aid initially pledged by the U.S. government.
Cramer makes the call on viewers' favorite stocks.
The traders are closely watching potential hot stocks ahead of the JPMorgan Health Care conference next week.
HMO stocks traded higher as some Dems predicted health care reform could pass as soon as Christmas Eve.
This morning biopharma P & A reached critical mass. In a rare, holiday-week confluence, four major pharmaceutical companies announced partnership deals and one announced a nearly $2-billion acquisition. All of the partnerships are on drugs that are still in the testing stage. If they were to all come to fruition, which in the risky business of drug development is highly unlikely, the new partnerships could collectively be worth billions of dollars over time.
How should investors prepare their portfolios for next year? Dan Genter, president, CEO and CIO of RNC Genter Capital Management, and Steven Stahler, president of Stahler Investment Group, shared their market outlooks.
The Dow and S&P closed higher on Thursday as investors bet on a year-end rally with money rotating into the technology sector.
Unease about the economy drove many investors to snap up defensive stocks. Should you do the same?
Masters’ Select International Fund, rated 5 stars by Morningstar, achieved 35.69 percent return so far this year with about $1.3 billion assets under management. Jeremy Degroot, portfolio manager of the fund, shared his best stock picks with CNBC.
Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!
Following are the day’s biggest winners and losers. Find out why shares of Barrick Gold and Research In Motion popped while Mastercard and Teva Pharma dropped.